Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Pulmonary surfactant protein SP-C regulates lipid vesicle uptake by alveolar type II cells and macrophages: Role of lipids, palmitoylation, and environment

  • Morán Lalangui, Juranny Michelle
  • Villoslada González, Marta
  • Hevia Lorenzo, Carmen
  • Pérez Gil, Jesús
  • García Álvarez, María Begoña
Pulmonary surfactant protein C (SP-C) may play a key role in alveolar homeostasis by modulating vesicle uptake in alveolar cells. This study explores how SP-C regulates internalization of model unilamellar lipid vesicles by type II alveolar epithelial cells (AECII) and alveolar macrophages (AMϕ), focusing on the effect of lipid composition, palmitoylation state, and interactions with external stimuli like lipopolysaccharides (LPS) or the other hydrophobic surfactant protein SP-B. Using fluorescence-based techniques, we demonstrated that SP-C enhances vesicle uptake in a lipid-dependent manner. While AECII internalize vesicles regardless of lipid composition, AMϕ show a preference for vesicles with specific lipid profiles. The palmitoylation of SP-C is essential for efficient vesicle uptake, highlighting the importance of membrane-protein interactions in this process. Furthermore, SP-C colocalizes with acidic organelles within both cell types, suggesting its involvement in intracellular trafficking and surfactant homeostasis. Notably, SP-C facilitates LPS uptake by AMϕ, potentially contributing to immune modulation in the alveolar spaces. The contribution of SP-C to metabolism and pulmonary immunity has important implications in lung diseases involving surfactant dysfunction or immune dysregulation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging

  • Piñeiro-Hermida, Sergio|||0000-0002-8915-5687
  • Autilio, Chiara
  • Martínez, Paula|||0000-0002-4655-5672
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Pérez-Gil, Jesús
  • Blasco, María A.|||0000-0002-4211-233X
Here, we show that physiological aging in mice leads to degenerative and fibrotic-like pathologies in the lung and that telomerase gene therapy prevents the onset of these pathologies. Our findings highlight telomerase activation as a potential therapeutic strategy for lung degenerative pathologies associated with aging. Short/dysfunctional telomeres are at the origin of idiopathic pulmonary fibrosis (IPF) in patients mutant for telomere maintenance genes. However, it remains unknown whether physiological aging leads to short telomeres in the lung, thus leading to IPF with aging. Here, we find that physiological aging in wild-type mice leads to telomere shortening and a reduced proliferative potential of alveolar type II cells and club cells, increased cellular senescence and DNA damage, increased fibroblast activation and collagen deposits, and impaired lung biophysics, suggestive of a fibrosis-like pathology. Treatment of both wild-type and telomerase-deficient mice with telomerase gene therapy prevented the onset of lung profibrotic pathologies. These findings suggest that short telomeres associated with physiological aging are at the origin of IPF and that a potential treatment for IPF based on telomerase activation would be of interest not only for patients with telomerase mutations but also for sporadic cases of IPF associated with physiological aging.